Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma.
Identifieur interne : 00BA57 ( Ncbi/Curation ); précédent : 00BA56; suivant : 00BA58Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma.
Auteurs : P. Würl [Allemagne] ; U. Eichfeld ; H D Pauer ; A. Gl Ser ; U. Rose ; H. DralleSource :
- Surgery today [ 0941-1291 ] ; 1997.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques alcoylants (administration et posologie), Bras, Circulation extracorporelle, Femelle, Humains, Hypothermie provoquée, Melphalan (administration et posologie), Mâle, Mélanome (), Perfusion régionale de chimiothérapie anticancéreuse (), Pronostic, Résultat thérapeutique, Sujet âgé.
- MESH :
- administration et posologie : Antinéoplasiques alcoylants, Melphalan.
- Adulte, Adulte d'âge moyen, Bras, Circulation extracorporelle, Femelle, Humains, Hypothermie provoquée, Mâle, Mélanome, Perfusion régionale de chimiothérapie anticancéreuse, Pronostic, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Agents, Alkylating (administration & dosage), Arm, Chemotherapy, Cancer, Regional Perfusion (methods), Extracorporeal Circulation, Female, Humans, Hypothermia, Induced, Male, Melanoma (therapy), Melphalan (administration & dosage), Middle Aged, Prognosis, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Alkylating, Melphalan.
- methods : Chemotherapy, Cancer, Regional Perfusion.
- therapy : Melanoma.
- Adult, Aged, Arm, Extracorporeal Circulation, Female, Humans, Hypothermia, Induced, Male, Middle Aged, Prognosis, Treatment Outcome.
Abstract
Isolated hyperthermic cytostatic limb perfusion has been established as an efficient procedure for the treatment of malignant melanoma of the limbs. However, perfusions of the upper extremities are generally carried out much less frequently than would be expected given the distribution pattern of malignant melanoma and sarcoma. Thus, isolated descriptions of treatment results for perfusion of the upper extremities are not available. Between 1991 and 1994, arm perfusions using melphalan 1.0 mg/kg body weight were given to 14 patients with malignant melanoma, using the standardized method of perfusion described herein. Within an average observation period of 34.9 months (range, 12-65 months), 11 (78.7%) of the 14 patients who had M.D. Anderson stage II-IV melanoma remained free of local recurrence. In fact, 10 (71.6%) of the patients were still alive at the end of the observation period. None of the 14 patients showed any systemic adverse effects, although 1 patient developed a lymphedema 32 months after perfusion and 2 patients showed a postoperative temporary neurologic deficit. These results demonstrate that isolated perfusion of the upper limb with heat and melphalan under standardized conditions remains the treatment of choice for melanoma of the arm, as for melanoma of the leg, without a higher rate of complications.
PubMed: 9306586
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005058
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :005058
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :005058
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :00BA57
Links to Exploration step
pubmed:9306586Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma.</title><author><name sortKey="Wurl, P" sort="Wurl, P" uniqKey="Wurl P" first="P" last="Würl">P. Würl</name><affiliation wicri:level="1"><nlm:affiliation>Department of General Surgery, Martin-Luther-University Halle, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of General Surgery, Martin-Luther-University Halle</wicri:regionArea><wicri:noRegion>Martin-Luther-University Halle</wicri:noRegion><wicri:noRegion>Martin-Luther-University Halle</wicri:noRegion><wicri:noRegion>Martin-Luther-University Halle</wicri:noRegion></affiliation></author><author><name sortKey="Eichfeld, U" sort="Eichfeld, U" uniqKey="Eichfeld U" first="U" last="Eichfeld">U. Eichfeld</name></author><author><name sortKey="Pauer, H D" sort="Pauer, H D" uniqKey="Pauer H" first="H D" last="Pauer">H D Pauer</name></author><author><name sortKey="Gl Ser, A" sort="Gl Ser, A" uniqKey="Gl Ser A" first="A" last="Gl Ser">A. Gl Ser</name></author><author><name sortKey="Rose, U" sort="Rose, U" uniqKey="Rose U" first="U" last="Rose">U. Rose</name></author><author><name sortKey="Dralle, H" sort="Dralle, H" uniqKey="Dralle H" first="H" last="Dralle">H. Dralle</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9306586</idno><idno type="pmid">9306586</idno><idno type="wicri:Area/PubMed/Corpus">005058</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005058</idno><idno type="wicri:Area/PubMed/Curation">005058</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005058</idno><idno type="wicri:Area/PubMed/Checkpoint">005058</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005058</idno><idno type="wicri:Area/Ncbi/Merge">00BA57</idno><idno type="wicri:Area/Ncbi/Curation">00BA57</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma.</title><author><name sortKey="Wurl, P" sort="Wurl, P" uniqKey="Wurl P" first="P" last="Würl">P. Würl</name><affiliation wicri:level="1"><nlm:affiliation>Department of General Surgery, Martin-Luther-University Halle, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of General Surgery, Martin-Luther-University Halle</wicri:regionArea><wicri:noRegion>Martin-Luther-University Halle</wicri:noRegion><wicri:noRegion>Martin-Luther-University Halle</wicri:noRegion><wicri:noRegion>Martin-Luther-University Halle</wicri:noRegion></affiliation></author><author><name sortKey="Eichfeld, U" sort="Eichfeld, U" uniqKey="Eichfeld U" first="U" last="Eichfeld">U. Eichfeld</name></author><author><name sortKey="Pauer, H D" sort="Pauer, H D" uniqKey="Pauer H" first="H D" last="Pauer">H D Pauer</name></author><author><name sortKey="Gl Ser, A" sort="Gl Ser, A" uniqKey="Gl Ser A" first="A" last="Gl Ser">A. Gl Ser</name></author><author><name sortKey="Rose, U" sort="Rose, U" uniqKey="Rose U" first="U" last="Rose">U. Rose</name></author><author><name sortKey="Dralle, H" sort="Dralle, H" uniqKey="Dralle H" first="H" last="Dralle">H. Dralle</name></author></analytic><series><title level="j">Surgery today</title><idno type="ISSN">0941-1291</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Agents, Alkylating (administration & dosage)</term><term>Arm</term><term>Chemotherapy, Cancer, Regional Perfusion (methods)</term><term>Extracorporeal Circulation</term><term>Female</term><term>Humans</term><term>Hypothermia, Induced</term><term>Male</term><term>Melanoma (therapy)</term><term>Melphalan (administration & dosage)</term><term>Middle Aged</term><term>Prognosis</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques alcoylants (administration et posologie)</term><term>Bras</term><term>Circulation extracorporelle</term><term>Femelle</term><term>Humains</term><term>Hypothermie provoquée</term><term>Melphalan (administration et posologie)</term><term>Mâle</term><term>Mélanome ()</term><term>Perfusion régionale de chimiothérapie anticancéreuse ()</term><term>Pronostic</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents, Alkylating</term><term>Melphalan</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques alcoylants</term><term>Melphalan</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemotherapy, Cancer, Regional Perfusion</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Arm</term><term>Extracorporeal Circulation</term><term>Female</term><term>Humans</term><term>Hypothermia, Induced</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Bras</term><term>Circulation extracorporelle</term><term>Femelle</term><term>Humains</term><term>Hypothermie provoquée</term><term>Mâle</term><term>Mélanome</term><term>Perfusion régionale de chimiothérapie anticancéreuse</term><term>Pronostic</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Isolated hyperthermic cytostatic limb perfusion has been established as an efficient procedure for the treatment of malignant melanoma of the limbs. However, perfusions of the upper extremities are generally carried out much less frequently than would be expected given the distribution pattern of malignant melanoma and sarcoma. Thus, isolated descriptions of treatment results for perfusion of the upper extremities are not available. Between 1991 and 1994, arm perfusions using melphalan 1.0 mg/kg body weight were given to 14 patients with malignant melanoma, using the standardized method of perfusion described herein. Within an average observation period of 34.9 months (range, 12-65 months), 11 (78.7%) of the 14 patients who had M.D. Anderson stage II-IV melanoma remained free of local recurrence. In fact, 10 (71.6%) of the patients were still alive at the end of the observation period. None of the 14 patients showed any systemic adverse effects, although 1 patient developed a lymphedema 32 months after perfusion and 2 patients showed a postoperative temporary neurologic deficit. These results demonstrate that isolated perfusion of the upper limb with heat and melphalan under standardized conditions remains the treatment of choice for melanoma of the arm, as for melanoma of the leg, without a higher rate of complications.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00BA57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 00BA57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:9306586
|texte= Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:9306586" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |